4.7 Review

The Emerging Role of Sfrp5 and Wnt5a in the Pathogenesis of Obesity: Implications for a Healthy Diet and Lifestyle

Journal

NUTRIENTS
Volume 13, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/nu13072459

Keywords

SFRP5; Wnt5a; overweight; obesity; childhood; metabolic

Funding

  1. European Regional Development Fund of the European Union
  2. Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE [T1EDK-01386, MIS: 5030543]

Ask authors/readers for more resources

Obesity has dramatically increased globally in recent decades, characterized by excess fat accumulation and chronic low-grade inflammation. The adipokines Sfrp5 and Wnt5a are emerging as key players in the pathogenesis of obesity and metabolic complications, signaling via the non-canonical Wnt pathway. Further research is needed to explore their potential as biomarkers for lifestyle interventions and therapeutic targets for obesity-related disorders.
In recent decades, the prevalence of obesity has risen dramatically worldwide among all age groups. Obesity is characterized by excess fat accumulation and chronic low-grade inflammation. The adipose tissue functions as a metabolically active endocrine organ secreting adipokines. A novel duo of adipokines, the anti-inflammatory secreted frizzled-related protein 5 (Sfrp5) and the proinflammatory wingless type mouse mammary tumor virus (MMTV) integration site family member 5A (Wnt5a), signal via the non-canonical Wnt pathway. Recent evidence suggests that Sfpr5 and Wnt5a play a key role in the pathogenesis of obesity and its metabolic complications. This review summarizes the current knowledge on the novel regulatory system of anti-inflammatory Sfrp5 and pro-inflammatory Wnt5a, and their relation to obesity and obesity-related complications. Future studies are required to investigate the potential role of Sfrp5 and Wnt5a as biomarkers for monitoring the response to lifestyle interventions and for predicting the development of cardiometabolic risk factors. These adipokines may also serve as novel therapeutic targets for obesity-related disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available